Capital International Investors Seagen Inc. Transaction History

Capital International Investors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $877 Million - $990 Million	-4,581,826 Reduced 71.4%	1,835,398 $389 Million
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $1.58 Billion - $1.74 Billion	-8,429,389 Reduced 56.78%	6,417,224 $1.24 Billion
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $222 Million - $353 Million	-1,737,847 Reduced 10.48%	14,846,613 $3.01 Billion
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $120 Million - $142 Million	1,019,610 Added 6.55%	16,584,460 $2.13 Billion
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $4.5 Million - $5.99 Million	33,257 Added 0.21%	15,564,850 $2.13 Billion
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $7.21 Million - $11.9 Million	66,235 Added 0.43%	15,531,593 $2.75 Billion
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $473 Million - $624 Million	3,953,818 Added 34.35%	15,465,358 $2.23 Billion
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $197 Million - $264 Million	-1,381,970 Reduced 10.72%	11,511,540 $1.78 Billion
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $416 Million - $495 Million	-2,917,355 Reduced 18.45%	12,893,510 $2.19 Billion
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $21.7 Million - $25.8 Million	160,311 Added 1.02%	15,810,865 $2.5 Billion
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $344 Million - $478 Million	-2,504,534 Reduced 13.8%	15,650,554 $2.17 Billion
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $2.99 Billion - $3.85 Billion	18,155,088 New	18,155,088 $3.18 Billion

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.